Andrea R Marcadis1, Pablo Valderrabano2, Allen S Ho3, Justin Tepe1, Christina E Swartzwelder1, Serena Byrd1, Wendy L Sacks4, Brian R Untch1, Ashok R Shaha1, Bin Xu5, Oscar Lin5, Ronald A Ghossein5, Richard J Wong1, Jennifer L Marti6, Luc G T Morris7. 1. Department of Surgery (Head and Neck Service), Memorial Sloan Kettering Cancer Center, New York, NY. 2. Department of Head and Neck Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. 3. Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA. 4. Department of Endocrinology, Cedars-Sinai Medical Center, Los Angeles, CA. 5. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY. 6. Department of Surgery, New York Presbyterian/Weill Cornell Medical Center, New York, NY. 7. Department of Surgery (Head and Neck Service), Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: morrisl@mskcc.org.
Abstract
BACKGROUND: The ThyroSeq v2 next-generation sequencing assay estimates the probability of malignancy in indeterminate thyroid nodules. Its diagnostic accuracy in different practice settings and patient populations is not well understood. METHODS: We analyzed 273 Bethesda III/IV indeterminate thyroid nodules evaluated with ThyroSeq at 4 institutions: 2 comprehensive cancer centers (n = 98 and 102), a multicenter health care system (n = 60), and an academic medical center (n = 13). The positive and negative predictive values of ThyroSeq and distribution of final pathologic diagnoses were analyzed and compared with values predicted by Bayes theorem. RESULTS: Across 4 institutions, the positive predictive value was 35% (22%-43%) and negative predictive value was 93% (88%-100%). Predictive values correlated closely with Bayes theorem estimates (r2 = 0.84), although positive predictive values were lower than expected. RAS mutations were the most common molecular alteration. Among 84 RAS-mutated nodules, malignancy risk was variable (25%, range 10%-37%) and distribution of benign diagnoses differed across institutions (adenoma/hyperplasia 12%-85%, noninvasive follicular thyroid neoplasm with papillary-like nuclear features 5%-46%). CONCLUSION: In a multi-institutional analysis, ThyroSeq positive predictive values were variable and lower than expected. This is attributable to differences in the prevalence of malignancy and variability in pathologist interpretations of noninvasive tumors. It is important that clinicians understand ThyroSeq performance in their practice setting when evaluating these results. Crown
BACKGROUND: The ThyroSeq v2 next-generation sequencing assay estimates the probability of malignancy in indeterminate thyroid nodules. Its diagnostic accuracy in different practice settings and patient populations is not well understood. METHODS: We analyzed 273 Bethesda III/IV indeterminate thyroid nodules evaluated with ThyroSeq at 4 institutions: 2 comprehensive cancer centers (n = 98 and 102), a multicenter health care system (n = 60), and an academic medical center (n = 13). The positive and negative predictive values of ThyroSeq and distribution of final pathologic diagnoses were analyzed and compared with values predicted by Bayes theorem. RESULTS: Across 4 institutions, the positive predictive value was 35% (22%-43%) and negative predictive value was 93% (88%-100%). Predictive values correlated closely with Bayes theorem estimates (r2 = 0.84), although positive predictive values were lower than expected. RAS mutations were the most common molecular alteration. Among 84 RAS-mutated nodules, malignancy risk was variable (25%, range 10%-37%) and distribution of benign diagnoses differed across institutions (adenoma/hyperplasia 12%-85%, noninvasive follicular thyroid neoplasm with papillary-like nuclear features 5%-46%). CONCLUSION: In a multi-institutional analysis, ThyroSeq positive predictive values were variable and lower than expected. This is attributable to differences in the prevalence of malignancy and variability in pathologist interpretations of noninvasive tumors. It is important that clinicians understand ThyroSeq performance in their practice setting when evaluating these results. Crown
Authors: Tarik M Elsheikh; Sylvia L Asa; John K C Chan; Ronald A DeLellis; Clara S Heffess; Virginia A LiVolsi; Bruce M Wenig Journal: Am J Clin Pathol Date: 2008-11 Impact factor: 2.493
Authors: Yuri E Nikiforov; Raja R Seethala; Giovanni Tallini; Zubair W Baloch; Fulvio Basolo; Lester D R Thompson; Justine A Barletta; Bruce M Wenig; Abir Al Ghuzlan; Kennichi Kakudo; Thomas J Giordano; Venancio A Alves; Elham Khanafshar; Sylvia L Asa; Adel K El-Naggar; William E Gooding; Steven P Hodak; Ricardo V Lloyd; Guy Maytal; Ozgur Mete; Marina N Nikiforova; Vania Nosé; Mauro Papotti; David N Poller; Peter M Sadow; Arthur S Tischler; R Michael Tuttle; Kathryn B Wall; Virginia A LiVolsi; Gregory W Randolph; Ronald A Ghossein Journal: JAMA Oncol Date: 2016-08-01 Impact factor: 31.777
Authors: Pablo Valderrabano; Marino E Leon; Barbara A Centeno; Kristen J Otto; Laila Khazai; Judith C McCaffrey; Jeffery S Russell; Bryan McIver Journal: Eur J Endocrinol Date: 2016-02-22 Impact factor: 6.664
Authors: Pablo Valderrabano; Laila Khazai; Marino E Leon; Zachary J Thompson; Zhenjun Ma; Christine H Chung; Julie E Hallanger-Johnson; Kristen J Otto; Kara D Rogers; Barbara A Centeno; Bryan McIver Journal: Endocr Relat Cancer Date: 2017-01-19 Impact factor: 5.678
Authors: Jennifer L Marti; Vaidehi Avadhani; Luke A Donatelli; Sayani Niyogi; Beverly Wang; Richard J Wong; Ashok R Shaha; Ronald A Ghossein; Oscar Lin; Luc G T Morris; Allen S Ho Journal: Ann Surg Oncol Date: 2015-04-11 Impact factor: 5.344
Authors: Wendy L Sacks; Shikha Bose; Zachary S Zumsteg; Ronnie Wong; Stephen L Shiao; Glenn D Braunstein; Allen S Ho Journal: Cancer Cytopathol Date: 2016-06-27 Impact factor: 5.284
Authors: Ricardo V Lloyd; Lori A Erickson; Mary B Casey; King Y Lam; Christine M Lohse; Sylvia L Asa; John K C Chan; Ronald A DeLellis; H Ruben Harach; Kennichi Kakudo; Virginia A LiVolsi; Juan Rosai; Thomas J Sebo; Manuel Sobrinho-Simoes; Bruce M Wenig; Marick E Lae Journal: Am J Surg Pathol Date: 2004-10 Impact factor: 6.394
Authors: Yuri E Nikiforov; Sally E Carty; Simon I Chiosea; Christopher Coyne; Umamaheswar Duvvuri; Robert L Ferris; William E Gooding; Steven P Hodak; Shane O LeBeau; N Paul Ohori; Raja R Seethala; Mitchell E Tublin; Linwah Yip; Marina N Nikiforova Journal: Cancer Date: 2014-09-10 Impact factor: 6.860
Authors: Juan C Hernandez-Prera; Pablo Valderrabano; Jordan H Creed; Janis V de la Iglesia; Robbert J C Slebos; Barbara A Centeno; Valentina Tarasova; Julie Hallanger-Johnson; Colleen Veloski; Kristen J Otto; Bruce M Wenig; Sean J Yoder; Cesar A Lam; Derek S Park; Alexander R Anderson; Natarajan Raghunand; Anders Berglund; Jimmy Caudell; Travis A Gerke; Christine H Chung Journal: Thyroid Date: 2020-08-25 Impact factor: 6.568
Authors: John Woody Sistrunk; Alexander Shifrin; Marc Frager; Ricardo H Bardales; Johnson Thomas; Norman Fishman; Philip Goldberg; Richard Guttler; Edward Grant Journal: Diagn Cytopathol Date: 2019-04-23 Impact factor: 1.582
Authors: Mark A Lupo; Ann E Walts; J Woody Sistrunk; Thomas J Giordano; Peter M Sadow; Nicole Massoll; Ryan Campbell; Sara A Jackson; Nicole Toney; Christina M Narick; Gyanendra Kumar; Alidad Mireskandari; Sydney D Finkelstein; Shikha Bose Journal: Diagn Cytopathol Date: 2020-08-07 Impact factor: 1.582